Abstract
Although an increased oxidative stress has been associated with several pathologies, predictive value of circulating oxidative stress biomarkers remains poorly understood. It has been demonstrated that several pathologies underestimated in women, including cardiovascular diseases, develop differently by gender. In this study, conducted on 195 healthy volunteers, we assessed the putative gender difference in prooxidant and antioxidant status. Our results were successful in demonstrating a significant difference in oxidative stress between sexes, whereas no difference was found in the plasma antioxidant barrier efficiency. To assess whether this difference was due to hormonal status (i.e. estrogen levels), female samples were divided into pre-menopausal and post-menopausal groups. No significant difference emerged for both biomarkers. Despite the well-known antioxidant estrogen role, women in this study presented a higher oxidative status than males. This suggests that there is a difference in the production and metabolic deactivation of reactive oxygen metabolite.
Keywords: Antioxidant capacity, gender differences, healthy subject, oxidative stress, predictive biomarkers, reactive oxygen species.
Current Drug Targets
Title:Sex Differences in Oxidative Stress Biomarkers
Volume: 15 Issue: 8
Author(s): Elvira Brunelli, Francesco Domanico, Daniele La Russa and Daniela Pellegrino
Affiliation:
Keywords: Antioxidant capacity, gender differences, healthy subject, oxidative stress, predictive biomarkers, reactive oxygen species.
Abstract: Although an increased oxidative stress has been associated with several pathologies, predictive value of circulating oxidative stress biomarkers remains poorly understood. It has been demonstrated that several pathologies underestimated in women, including cardiovascular diseases, develop differently by gender. In this study, conducted on 195 healthy volunteers, we assessed the putative gender difference in prooxidant and antioxidant status. Our results were successful in demonstrating a significant difference in oxidative stress between sexes, whereas no difference was found in the plasma antioxidant barrier efficiency. To assess whether this difference was due to hormonal status (i.e. estrogen levels), female samples were divided into pre-menopausal and post-menopausal groups. No significant difference emerged for both biomarkers. Despite the well-known antioxidant estrogen role, women in this study presented a higher oxidative status than males. This suggests that there is a difference in the production and metabolic deactivation of reactive oxygen metabolite.
Export Options
About this article
Cite this article as:
Brunelli Elvira, Domanico Francesco, Russa La Daniele and Pellegrino Daniela, Sex Differences in Oxidative Stress Biomarkers, Current Drug Targets 2014; 15 (8) . https://dx.doi.org/10.2174/1389450115666140624112317
DOI https://dx.doi.org/10.2174/1389450115666140624112317 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IL-1 Cytokines in Cardiovascular Disease: Diagnostic, Prognostic and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolic Therapy: Lessons from Liver Diseases
Current Pharmaceutical Design Angiogenesis Imaging Using 68Ga-RGD PET: Preliminary Report from Seoul National University Hospital
Current Medical Imaging Effects of Hypertension, Diabetes Mellitus, Obesity and Other Factors on Kidney Haemodynamics
Current Vascular Pharmacology EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Current Alzheimer Research Symptoms in Dilating Venous Disease
Current Cardiology Reviews Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile
Current Pharmaceutical Design Cystatin C in Cerebrovascular Disorders
Current Neurovascular Research Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Which are the Best Follow-Up Strategies for Patients Who Undergo Percutaneous Coronary Interventions?
Current Cardiology Reviews Modulation of Renin-Angiotensin System and Arterial Stiffness: Evidence from Clinical Trials
Current Hypertension Reviews Molecular Imaging with Nucleic Acid Aptamers
Current Medicinal Chemistry Insights into Oxidative Stress: The Isoprostanes
Current Medicinal Chemistry CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Uteroplacental Circulation and Fetal Vascular Function and Development
Current Vascular Pharmacology Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection
Current Diabetes Reviews Liver Transporters in Hepatic Drug Disposition: An Update
Current Drug Metabolism Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials The Prostaglandin Agonist Beraprost Aggravates Doxorubicin-mediated Apoptosis by Increasing iNOS Expression in Cardiomyocytes
Current Vascular Pharmacology